Point72 Middle East FZE’s Abivax ABVX Stock Holding History

Point72 Middle East FZE’s Portfolio ABVX Stock Details ABVX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-51,002	Closed	-$546K	–	14
2023 Q4	$546K	Buy	+51,002	New	+$520K	0.02%	800

Other funds holding ABVX

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Blackstone Inc New York $25.6B AUM 26.83% 1-Year Est. Return

Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return

Franklin Resources

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return

Point72 Middle East FZE's ABVX Position: Q1 2024 in Review

Point72 Middle East FZE sold out of Abivax (ABVX) in Q1 2024, closing a stake of 51,002 shares — an estimated $546K sold.

Point72 Middle East FZE first reported a position in ABVX in Q4 2023 and held it in 1 quarter. The position peaked at $546K in Q4 2023. 36 funds tracked by Wall St. Rank hold ABVX as of Q1 2024.

Point72 Middle East FZE reported no remaining Abivax position as of Q1 2024 after selling out during the quarter.
Point72 Middle East FZE sold 51,002 Abivax shares in Q1 2024, an estimated $546K.
Point72 Middle East FZE first reported a position in Abivax in Q4 2023 and held it in 1 quarter.
Point72 Middle East FZE's Abivax position peaked at $546K in Q4 2023.
36 funds tracked by Wall St. Rank held Abivax as of Q1 2024.

Based on Point72 Middle East FZE's 13F filing for Q1 2024.